ARQT
What one share of Arcutis Biotherapeutics holds
Pharmaceutical Preparations
We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions.
Arcutis Biotherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.52 |
|---|---|
| Profit | $0.22 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.30 |
| Cash and investments | $0.27 |
| Debt | $0.87 |
| Book value | $1.76 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$15.53 | $0.00 | −$11.36 | — | −$19.35 |
| 2019 | — | −$22.78 | $0.16 | −$23.40 | — | −$30.66 |
| 2020 | $0.00 | −$3.80 | $0.01 | −$3.18 | — | $6.24 |
| 2021 | $0.00 | −$4.18 | $0.02 | −$3.55 | — | $5.92 |
| 2022 | $0.07 | −$5.66 | $0.01 | −$4.69 | — | $3.43 |
| 2023 | $0.86 | −$3.78 | $0.01 | −$3.57 | — | $0.92 |
| 2024 | $1.62 | −$1.16 | $0.00 | −$0.93 | — | $1.34 |
| 2025 | $2.96 | −$0.13 | $0.01 | −$0.05 | — | $1.54 |